All In Biotech

Drug Trial Radar · NCT07870330

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

96

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Dec 7, 2027

Study completion Dec 7, 2027

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to \<18 years of age).

Conditions

  • Seasonal Influenza

Interventions

  • mRNA-1010Biological

    Suspension for injection

  • Fluarix TrivalentBiological

    Suspension for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)Time frame: Up to Day 7 (7 days after vaccination)
  2. Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 28 (28 days after vaccination)
  3. Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)Time frame: Day 1 through Day 365
  4. Number of Participants with Medically Attended AEs (MAAEs)Time frame: Day 1 through Day 181
  5. Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) AssayTime frame: Day 29
  6. Percentage of Participants Reaching Seroconversion, as Measured by HAI AssayTime frame: Day 29
  7. Percentage of Participants With HAI Titer ≥ 1:40 at Day 29Time frame: Day 29
  8. Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI AssaysTime frame: Day 29

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Paradigm Clinical Research Centers, LLC

    Modesto, California · Recruiting

  • Paradigm Clinical Research Centers, LLC

    Aurora, Colorado · Recruiting

  • Clinical Research Institute, Inc

    Minneapolis, Minnesota · Recruiting

  • Senders Pediatrics

    South Euclid, Ohio · Recruiting

  • West Houston Clinical Research Service

    Houston, Texas · Recruiting

  • Clinical Research Partners, LLC.

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.